Three companies in the health sector, the French diagnostics company BioMérieux and the German laboratories Evotech and Boehringer Ingelheim, will form a joint venture to find new antibiotics in the face of the growing problem of antibiotic resistance.
This new Lyon-based company, Aurobac Therapeutics, will be responsible for developing a new clinical approach from diagnosis to treatment, they said in a joint press release on Wednesday.
Aurobac is financed to the tune of 30 million euros by Boehringer Ingelheim and 5 million euros each by Evotec and bioMérieux.
Its objective is to fight against antibiotic resistance, which today constitutes a major threat. By various mechanisms, antibiotics, which represent the majority of drugs in circulation, gradually lose their effectiveness against bacteria.
The overconsumption of these treatments in human health and their overconsumption in animal health are particularly isolated to explain the phenomenon.
Every year in the EU, 25,000 people die from antibiotic resistance, according to EU officials.
Conventional surgical procedures such as cesarean sections or hip prosthesis implants, for example, can be life-threatening to the patient, the press release states.
Aurobac will work to develop a strategy linked to current therapies based on approaches using broad-spectrum and non-targeted antibiotics.
Its goal is to develop new targeted solutions related to rapid diagnosis, including tests that enable the rapid identification of pathogens and their resistance profiles, the companies said.